Skip to main content

Research News

photo of salim lab
Assistant Professor Samina Salim, Ph.D., third from left, whose lab is investigating the impact of oxidative stress in anxiety, was among the UHCOP faculty researchers who earned new funding from the National Institutes of Health in fiscal year 2014-15.

Record Research Year

$7.6 M in Research Funding for FY2014-15 Sets New College Record

UH College of Pharmacy achieved a new college record of $7.64 million in grant support during the 2014-15 Fiscal Year, surpassing the previous record of slightly more than $6 million in 2010. 

Among the factors contributing to the year's success were several new multiyear R01 and R15 awards from the National Institutes of Health as well as the hiring of new faculty with significant current or post-appointment NIH funding awards. Highlights include awards of: 

  • $1.79 million to Associate Professor Joydip Das, Ph.D., from the National Institute on Alcohol and Alcohol Abuse;
  • $451,500 to Associate Professor Bradley McConnell, Ph.D., from the National Heart, Blood and Lung Institute (NHBLI); 
  • $451,500 to Assistant Professor Samina Salim, Ph.D., from the National Institute of Mental Health; and
  • $3.4 million to Associate Professor Yang Zhang, Ph.D., from the NHBLI.

"This new record is the result of work by our faculty to develop and submit high-scoring proposals to conduct high-impact basic, clinical and translational research projects that will improve the health of Texans, Americans and patients around the world," said UHCOP Dean F. Lamar Pritchard, Ph.D., R.Ph. "It also underscores the importance continuing our efforts to attract researchers who will make an immediate impact in life-saving and quality of life-enhancing drug discovery and development as part of the University of Houston and the College of Pharmacy's shared Tier One mission."

With construction under way on the new UHCOP home in Health & Biomedical Sciences Building 2, the college is committed to creating and implementing innovative, interprofessional patient-centered care models as well as discovering novel drug targets and developing cutting-edge therapeutics to achieve optimal health outcomes for our patients at the local, national and international level. HBSB2 is scheduled for completion on June 28, 2017.